dr. barr on updated resonate data in ighv-mutant cll
Published 5 years ago • 211 plays • Length 1:55Download video MP4
Download video MP3
Similar videos
-
1:34
dr. byrd on updated resonate findings in cll
-
1:55
paul m. barr, md, elaborates on outcomes from the resonate trial in relapsed/refractory cll
-
1:39
dr. barr on umbralisib/ublituximab/venetoclax in relapsed/refractory cll
-
3:13
mutation status throughout the cll clinical course
-
1:29
dr. jennifer brown on resonate 2 trial in cll
-
0:39
dr. jennifer brown on mutations and targets in cll
-
7:37
resonate, resonate-2 and helios: three major clinical trials in cll research
-
2:59
reducing the risks of chemotherapy in ighv-mutated cll
-
1:44
proton therapy for brain and central nervous system tumors with dr. lia halasz
-
1:42
q-gen cell therapeutics developing cell therapy for cancer with alloplex
-
7:23
study of ribociclib and pdr001 in hr metastatic breast cancer
-
1:09
dr. byrd on long-term safety data with ibrutinib in cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
1:59
paul m. barr, md, offers opinion on ibrutinib in 1st line chronic lymphocytic leukemia
-
1:26
resonate: ibrutinib associated with favourable pfs and os in cll
-
1:30
undetectable minimal residual disease (umrd) explained
-
2:14
b-cell receptor (bcr) inhibitor response criteria in cll
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
2:02
dr. john byrd summarizes the resonate study findings
-
1:12
dr. brown on lessons learned from resonate-2 trial for cll
-
38:13
part 3 - expert guidance on management of cll patients with acalabrutinib - prof. peter hillmen, uk
-
1:43
resonate-1 and 2 trials and real-world data